S
Suzhou Meichuang Medical Technology
Medical device manufacturer revolutionizes patient care with innovative endoscopic solutions
About Suzhou Meichuang Medical Technology
Suzhou Meichuang Medical Technology Co., Ltd. ("Meichuang Medical") is a medical device company established in February 2021, focusing on developing and commercializing high-end devices for peripheral vascular intervention, tumor intervention, and hemodialysis access maintenance. The company was founded by Liu Wenjing, who serves as Chairman and CEO and has over 30 years of experience in the peripheral vascular and tumor intervention field. His journey to founding Meichuang Medical was driven by the realization that mastering core technology was essential for long-term viability, a conclusion reached after experiencing market volatility and supply chain vulnerabilities while acting as a Chinese distributor for imported medical products.
The company's core strategic advantage lies in its successful development and mass production of medical-grade expanded polytetrafluoroethylene (ePTFE), a critical material for high-end devices like vascular stent-grafts and artificial blood vessels. This achievement positions Meichuang as the first domestic company in China to scale the production of this material, breaking a long-standing monopoly held by foreign corporations and addressing a key bottleneck in the domestic supply chain. The company's business model is centered on leveraging this proprietary material platform to develop a diversified product pipeline while also supplying customized ePTFE materials to other device manufacturers. This dual approach mitigates supply chain risks for its partners and accelerates the product development cycle. The company generates revenue through the sale of its medical devices and core material components.
Meichuang Medical operates a global R&D footprint with a 5,400 sq. meter R&D and manufacturing base at its headquarters in Suzhou, a 1,300 sq. meter R&D center in Shanghai, and a new technology research hub in California, USA. This structure supports a robust pipeline that includes various stent-grafts, artificial blood vessels, and patches. The company has already secured certification for 15 products. To fuel its growth, Meichuang has attracted significant investment, completing multiple funding rounds, including an over 100 million RMB A+ round in January 2025 and a B round of a similar scale in June 2025, with participation from notable investors like HongShan (formerly Sequoia China), Efeng Capital, and Su Venture Capital.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 22.3/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- medical implants, Surgery, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jun 2025 | $14M | $55M | Zhejiang Paradise Silicon Valley Asset Management Group · Su Venture Capital · VCBeat | ↗ |
| SERIES A✓Equity / VC | Jan 2025 | $14M | $55M | Tsing Song Capital · Industrial Securities Capital · HSG · Efung Capital | ↗ |
Growth signals
Latest recorded traffic for Suzhou Meichuang Medical Technology is 1.1K monthly website visits, up 189.5% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Suzhou Meichuang Medical Technology in the Suzhou Shi ecosystem
The Suzhou Meichuang Medical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
HSG- ECEfung Capital
Tsing Song Capital
Industrial Securities CapitalZhejiang Paradise Silicon Valley Asset Management Group
- SCSu Venture Capital
VCBeat
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Suzhou Meichuang Medical Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Suzhou Meichuang Medical Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







